Rapport Therapeutics (RAPP) News Today $22.23 +0.04 (+0.18%) (As of 10:12 AM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period LMR Partners LLP Reduces Stock Holdings in Rapport Therapeutics (NASDAQ:RAPP)LMR Partners LLP lowered its holdings in Rapport Therapeutics (NASDAQ:RAPP - Free Report) by 60.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 20,000 shares of the company's stock after selling 30,000 shares durNovember 20 at 4:55 AM | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Shares Down 6.5% - Time to Sell?Rapport Therapeutics (NASDAQ:RAPP) Stock Price Down 6.5% - Here's WhyNovember 15, 2024 | marketbeat.comRapport Therapeutics to Present Data at American Epilepsy Society Annual MeetingNovember 14, 2024 | globenewswire.comRapport Therapeutics Reports Q3 Financials and Strategic UpdatesNovember 9, 2024 | tipranks.comRapport Therapeutics to Present at Stifel Healthcare Conference and Jefferies London Healthcare Conference in NovemberNovember 4, 2024 | globenewswire.comRapport Therapeutics (NASDAQ:RAPP) Shares Gap Up - What's Next?Rapport Therapeutics (NASDAQ:RAPP) Shares Gap Up - Here's What HappenedNovember 1, 2024 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Shares Down 4.2% - Time to Sell?Rapport Therapeutics (NASDAQ:RAPP) Shares Down 4.2% - Should You Sell?October 25, 2024 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Shares Gap Down - Time to Sell?Rapport Therapeutics (NASDAQ:RAPP) Shares Gap Down - Here's What HappenedOctober 21, 2024 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Trading Down 2.7% - Here's What HappenedRapport Therapeutics (NASDAQ:RAPP) Stock Price Down 2.7% - Time to Sell?October 18, 2024 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Hits New 52-Week High - Here's WhyRapport Therapeutics (NASDAQ:RAPP) Reaches New 12-Month High - Time to Buy?October 16, 2024 | marketbeat.comMillennium Management LLC Makes New $2.72 Million Investment in Rapport Therapeutics (NASDAQ:RAPP)Millennium Management LLC acquired a new position in shares of Rapport Therapeutics (NASDAQ:RAPP - Free Report) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 116,782 shares of the company's stock, vOctober 16, 2024 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Sees Significant Increase in Short InterestRapport Therapeutics (NASDAQ:RAPP - Get Free Report) was the target of a large increase in short interest during the month of September. As of September 30th, there was short interest totalling 1,840,000 shares, an increase of 32.4% from the September 15th total of 1,390,000 shares. Based on an average daily volume of 159,300 shares, the days-to-cover ratio is presently 11.6 days. Approximately 10.2% of the shares of the company are sold short.October 15, 2024 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Stock Price Up 5.3% - What's Next?Rapport Therapeutics (NASDAQ:RAPP) Stock Price Up 5.3% - What's Next?October 14, 2024 | marketbeat.comThe Manufacturers Life Insurance Company Acquires Shares of 75,516 Rapport Therapeutics (NASDAQ:RAPP)The Manufacturers Life Insurance Company acquired a new stake in shares of Rapport Therapeutics (NASDAQ:RAPP - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 75,516 shares of the coOctober 11, 2024 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Shares Down 4.1% Rapport Therapeutics (NASDAQ:RAPP) Stock Price Down 4.1%October 2, 2024 | marketbeat.comLogos Global Management LP Makes New Investment in Rapport Therapeutics (NASDAQ:RAPP)Logos Global Management LP acquired a new stake in Rapport Therapeutics (NASDAQ:RAPP - Free Report) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 208,910 shares of the company's stock, valued at approximately $4,859,000. Logos Global ManagemOctober 1, 2024 | marketbeat.comPerceptive Advisors LLC Invests $17.40 Million in Rapport Therapeutics (NASDAQ:RAPP)Perceptive Advisors LLC bought a new stake in shares of Rapport Therapeutics (NASDAQ:RAPP - Free Report) during the 2nd quarter, according to its most recent filing with the SEC. The fund bought 748,183 shares of the company's stock, valued at approximately $17,403,000. Perceptive Advisors LLC owneSeptember 30, 2024 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Shares Up 6.2%Rapport Therapeutics (NASDAQ:RAPP) Trading 6.2% HigherSeptember 27, 2024 | marketbeat.comARCH Venture Management LLC Makes New $86.73 Million Investment in Rapport Therapeutics (NASDAQ:RAPP)ARCH Venture Management LLC bought a new stake in shares of Rapport Therapeutics (NASDAQ:RAPP - Free Report) in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund bought 3,728,738 shares of the company's stock, valued at approximately $86,730,000. Rapport TheSeptember 24, 2024 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Trading Down 2.4%Rapport Therapeutics (NASDAQ:RAPP) Stock Price Down 2.4%September 19, 2024 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Shares Up 4.7%Rapport Therapeutics (NASDAQ:RAPP) Trading Up 4.7%September 17, 2024 | marketbeat.comSofinnova Investments Inc. Buys Shares of 1,951,562 Rapport Therapeutics (NASDAQ:RAPP)Sofinnova Investments Inc. acquired a new stake in Rapport Therapeutics (NASDAQ:RAPP - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 1,951,562 shares of the company's stock, valued atSeptember 17, 2024 | marketbeat.comRapport semestriel Pilier 3 - 30 juin 2024September 17, 2024 | globenewswire.comRapport Therapeutics (NASDAQ:RAPP) Shares Gap Up to $19.00Rapport Therapeutics (NASDAQ:RAPP) Shares Gap Up to $19.00September 16, 2024 | marketbeat.comJohnson & Johnson Invests $58.11 Million in Rapport Therapeutics (NASDAQ:RAPP)Johnson & Johnson acquired a new stake in Rapport Therapeutics (NASDAQ:RAPP - Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 2,498,051 shares of the company's stock, valued at approximately $58,105,000. RapportSeptember 16, 2024 | marketbeat.comTD Asset Management Inc Invests $2.36 Million in Rapport Therapeutics (NASDAQ:RAPP)TD Asset Management Inc bought a new position in Rapport Therapeutics (NASDAQ:RAPP - Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 101,522 shares of the company's stock, valued at approximately $2,361,000. TD AsSeptember 13, 2024 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Stock Price Down 5.5%Rapport Therapeutics (NASDAQ:RAPP) Shares Down 5.5%September 11, 2024 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Shares Gap Up to $21.20Rapport Therapeutics (NASDAQ:RAPP) Shares Gap Up to $21.20September 5, 2024 | marketbeat.comRapport Therapeutics to Present at Upcoming Epilepsy Medical ConferencesSeptember 5, 2024 | globenewswire.comRapport Therapeutics (NASDAQ:RAPP) Trading 5.8% Higher Rapport Therapeutics (NASDAQ:RAPP) Stock Price Up 5.8%September 4, 2024 | marketbeat.comRapport Therapeutics to Present at 22nd Annual Morgan Stanley Global Healthcare Conference and TD Cowen's 4th Annual Novel Mechanisms in Neuropsychiatry SummitAugust 29, 2024 | globenewswire.comRapport Therapeutics (NASDAQ:RAPP) Shares Gap Up to $20.40Rapport Therapeutics (NASDAQ:RAPP) Shares Gap Up to $20.40August 28, 2024 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Stock Price Down 4.4%Rapport Therapeutics (NASDAQ:RAPP) Stock Price Down 4.4%August 27, 2024 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Trading 3.8% Higher Rapport Therapeutics (NASDAQ:RAPP) Stock Price Up 3.8%August 26, 2024 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Trading 2.5% Higher Rapport Therapeutics (NASDAQ:RAPP) Shares Up 2.5%August 20, 2024 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Trading Down 2.5%Rapport Therapeutics (NASDAQ:RAPP) Shares Down 2.5%August 15, 2024 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Stock Price Up 10.2%Rapport Therapeutics (NASDAQ:RAPP) Trading Up 10.2%August 13, 2024 | marketbeat.comThe 3 Best Healthcare Stocks to Buy in August 2024August 12, 2024 | investorplace.comRAPP Stock Earnings: Rapport Therapeutics Misses EPS for Q2 2024August 10, 2024 | investorplace.comRapport Therapeutics (NASDAQ:RAPP) Sets New 12-Month Low at $16.80Rapport Therapeutics (NASDAQ:RAPP) Sets New 1-Year Low at $16.80August 8, 2024 | marketbeat.com3 Under-The-Radar Healthcare Stocks to Buy for Outsized ReturnsAugust 6, 2024 | investorplace.comRapport Therapeutics (NASDAQ:RAPP) Shares Down 10.7% Rapport Therapeutics (NASDAQ:RAPP) Shares Down 10.7%August 5, 2024 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Trading Up 3%Rapport Therapeutics (NASDAQ:RAPP) Trading 3% HigherAugust 2, 2024 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Stock Price Down 8.9%Rapport Therapeutics (NASDAQ:RAPP) Stock Price Down 8.9%July 30, 2024 | marketbeat.comRapport Therapeutics to Present Data for TARPγ8 AMPAR Negative Modulator at IASP 2024 World Congress on PainJuly 29, 2024 | globenewswire.comRapport Therapeutics (NASDAQ:RAPP) Stock Price Up 11%Rapport Therapeutics (NASDAQ:RAPP) Trading 11% HigherJuly 23, 2024 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Shares Gap Up to $23.03Rapport Therapeutics (NASDAQ:RAPP) Shares Gap Up to $23.03July 19, 2024 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Hits New 52-Week High at $28.08Rapport Therapeutics (NASDAQ:RAPP) Reaches New 12-Month High at $28.08July 17, 2024 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Trading Up 5.2%Rapport Therapeutics (NASDAQ:RAPP) Shares Up 5.2%July 15, 2024 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Reaches New 52-Week High at $27.14Rapport Therapeutics (NASDAQ:RAPP) Hits New 1-Year High at $27.14July 11, 2024 | marketbeat.com Get Rapport Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RAPP and its competitors with MarketBeat's FREE daily newsletter. Email Address Tesla Execs are Freaking Out (Ad)It’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands on it. And Elon Musk has completely restructured Tesla to chase this opportunity. This is a once-in-a-lifetime opportunity that you don’t want to miss. Click here to get the details. RAPP Media Mentions By Week RAPP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RAPP News Sentiment▼0.770.46▲Average Medical News Sentiment RAPP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RAPP Articles This Week▼22▲RAPP Articles Average Week Get Rapport Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RAPP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies PTCT News Today MLTX News Today VRNA News Today AGIO News Today HCM News Today EWTX News Today XENE News Today DYN News Today BHC News Today MRUS News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RAPP) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rapport Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Rapport Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
